对基于结构的药物设计的深入研究可以为新型临床活性分子的开发提供重要线索。在本研究中,使用分子对接研究设计了二十六个新颖的吡唑并[1,5- a ]嘧啶类似物(6a - 6z)。设计的分子以高收率合成。使用IR,MS,1 H NMR和13 C NMR光谱进行合成分子的结构阐明。通过Alamar Blue测定法评价所有合成的化合物对H37Rv菌株的体外抗结核活性。大多数合成的化合物显示出有效的抗结核活性。在所有测试的化合物中6p,6g,6n和6h表现出有希望的抗结核活性。此外,对这些有效化合物进行了MDR-TB,XDR-TB和细胞毒性研究的评估。这些化合物均未显示出有效的细胞毒性。蛋白配体复合物的稳定性通过分子动力学模拟进一步评估了10 ns。所有这些结果表明,合成的化合物可能是进一步开发新的有效抗结核药的潜在线索。
4,5-Dioxo-imidazolinium Cation Activation of 1-Acyl-1-carbamoyl Oximes: Access to Cyanoformamides Using Dichloroimidazolidinedione
摘要:
Cyanoformamides are prevalent as versatile building blocks for accessing synthetically useful intermediates and biologically active compounds. The development of a milder, simpler, and more efficient approach to cyanoformamides is nontrivial. Herein, we demonstrate the effectiveness of 4,S-dioxo-imidazolinium cation activation for transforming 1-aryl-1-carbamoyl oximes to cyanoformamides. By making use of the readily available and highly modifiable dichloroimidazolidinediones (DCIDs), this novel method of activation offers reactivity remarkably greater than that of other reported protocols, exhibits a high functional group compatibility with mild conditions, and could be scaled up easily. More than 30 examples are demonstrated with good to excellent yields in short reaction times. This research not only provides a mild and efficient alternative approach to assembling a portfolio of cyanoformamides but also extends the dichloroimidazolidinedione-mediated chemistry to encompass the C-C bond cleavage reaction.
Iodine-DMSO mediated conversion of <i>N</i>-arylcyanothioformamides to <i>N</i>-arylcyanoformamides and the unexpected formation of 2-cyanobenzothiazoles
作者:Ziad Moussa、Zaher M. A. Judeh、Ahmed Alzamly、Saleh A. Ahmed、Harbi Tomah Al-Masri、Bassam Al-Hindawi、Faisal Rasool、Sara Saada
DOI:10.1039/d2ra00049k
日期:——
substrates to access new luciferin analogs. The structures of all new products were elucidated by multinuclear NMR spectroscopy and high accuracy mass spectral analysis. Crystal-structuredetermination by means of single-crystal X-ray diffraction was carried out on (4-bromophenyl)carbamoyl cyanide, 5,6-dimethoxybenzo[d]thiazole-2-carbonitrile, 5-(benzyloxy)benzo[d]oxazole-2-carbonitrile, 4,7-dimetho
氰基甲酰胺作为组装关键中间体和生物活性分子的有用成分无处不在。开发一种有效且简单的方法来处理这个主题是一个挑战。在此,我们证明了 I 2 -DMSO 氧化系统在从N制备N-芳基氰基甲酰胺中的有效性。-芳基氰基硫代甲酰胺。该合成方法具有条件温和、底物范围广、反应效率高等特点。此外,这种方法提供了一个很好的入口,可以专门提供 2-氰基苯并噻唑,它们是获得新荧光素类似物的有用底物。所有新产品的结构均通过多核核磁共振光谱和高精度质谱分析进行了阐明。用单晶X射线衍射对(4-溴苯基)氨基甲酰氰、5,6-二甲氧基苯并[ d ]噻唑-2-甲腈、5-(苄氧基)苯并[ d ]恶唑进行晶体结构测定-2-甲腈,4,7-二甲氧基苯并[ d]噻唑-2-甲腈和(5-碘-2,4-二甲氧基苯基)氨基甲酰氰,一种具有机理意义的关键中间体。
Structure-based design, synthesis and biological evaluation of a newer series of pyrazolo[1,5-a]pyrimidine analogues as potential anti-tubercular agents
作者:Palmi Modi、Shivani Patel、Mahesh Chhabria
DOI:10.1016/j.bioorg.2019.02.044
日期:2019.6
In-depth study of structure-based drug designing can provide vital leads for the development of novel, clinically active molecules. In this present study, twenty six novel pyrazolo[1,5-a]pyrimidineanalogues (6a-6z) were designed using molecular docking studies. The designed molecules were synthesized in good yields. Structural elucidation of the synthesized molecules was carried out using IR, MS,
对基于结构的药物设计的深入研究可以为新型临床活性分子的开发提供重要线索。在本研究中,使用分子对接研究设计了二十六个新颖的吡唑并[1,5- a ]嘧啶类似物(6a - 6z)。设计的分子以高收率合成。使用IR,MS,1 H NMR和13 C NMR光谱进行合成分子的结构阐明。通过Alamar Blue测定法评价所有合成的化合物对H37Rv菌株的体外抗结核活性。大多数合成的化合物显示出有效的抗结核活性。在所有测试的化合物中6p,6g,6n和6h表现出有希望的抗结核活性。此外,对这些有效化合物进行了MDR-TB,XDR-TB和细胞毒性研究的评估。这些化合物均未显示出有效的细胞毒性。蛋白配体复合物的稳定性通过分子动力学模拟进一步评估了10 ns。所有这些结果表明,合成的化合物可能是进一步开发新的有效抗结核药的潜在线索。
4,5-Dioxo-imidazolinium Cation Activation of 1-Acyl-1-carbamoyl Oximes: Access to Cyanoformamides Using Dichloroimidazolidinedione
Cyanoformamides are prevalent as versatile building blocks for accessing synthetically useful intermediates and biologically active compounds. The development of a milder, simpler, and more efficient approach to cyanoformamides is nontrivial. Herein, we demonstrate the effectiveness of 4,S-dioxo-imidazolinium cation activation for transforming 1-aryl-1-carbamoyl oximes to cyanoformamides. By making use of the readily available and highly modifiable dichloroimidazolidinediones (DCIDs), this novel method of activation offers reactivity remarkably greater than that of other reported protocols, exhibits a high functional group compatibility with mild conditions, and could be scaled up easily. More than 30 examples are demonstrated with good to excellent yields in short reaction times. This research not only provides a mild and efficient alternative approach to assembling a portfolio of cyanoformamides but also extends the dichloroimidazolidinedione-mediated chemistry to encompass the C-C bond cleavage reaction.